Entering text into the input field will update the search result below

Health plan in Northeast U.S. to cover Exact's Cologuard

  • Tufts Health Plan, with more than 1M members across Massachusetts and Rhode Island, will cover Exact Sciences' (EXAS +1%) Cologuard colorectal cancer screening test effective March 15.
  • The FDA approved the test in August 2014, which the company offers as a service from its in-house laboratory. It generated $1.5M in revenues last year.

Recommended For You

About EXAS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EXAS--
Exact Sciences Corporation